BioMarin Pharmaceuticals
BMRN
BMRN
554 hedge funds and large institutions have $15.2B invested in BioMarin Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 89 funds opening new positions, 194 increasing their positions, 192 reducing their positions, and 80 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
554
Holders Change
–
Holders Change %
0%
% of All Funds
8.06%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
89
Increased
194
Reduced
192
Closed
80
Calls
$153M
Puts
$166M
Net Calls
-$13.1M
Net Calls Change
+$28M
Top Buyers
| 1 |
BlackRock
New York
|
+$680M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$261M |
| 3 |
State Street
Boston,
Massachusetts
|
+$226M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$72.2M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$70M |
Top Sellers
| 1 |
UBS Group
Zurich,
Switzerland
|
-$385M |
| 2 |
Barclays
London,
United Kingdom
|
-$341M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$145M |
| 4 |
Nomura Holdings
Tokyo,
Japan
|
-$130M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$118M |
